Advancing Patented Cannabinoid Science Into Drug Development
GreenWay Herbal Products, LLC is an intellectual property holding and licensing company advancing a patented, defined-spectrum cannabinoid drug candidate toward regulated pharmaceutical development. Our estate — originated from $2.5M in university-funded research and first filed in 2019 — now spans 14 national and regional patents and applications across two families, in the United States, Europe, the United Kingdom, Canada, Israel and Thailand.
GreenWay Herbal Products, LLC is a research-driven company focused on the discovery, patenting, and development of novel cannabinoid compositions with therapeutic potential.
Our work bridges academic research, intellectual property, and translational drug development.
Intellectual Property
Two granted U.S. patents, a granted European patent validated in 11 countries, and two granted UK patents — plus seven additional pending filings across the US, EU, Canada, Israel and Thailand.
Research Origin
Originated in 2016 through university-funded research, including an exclusive agreement with the world's largest medicinal plant repository.
Drug Development Focus
Granted U.S. claims cover methods of treating inflammation and autoimmune conditions — including rheumatoid arthritis, Crohn's disease, multiple sclerosis, psoriatic disease, scleroderma and systemic lupus.
Patent-Backed Cannabinoid Innovation
GreenWay Herbal Products holds granted intellectual property covering a novel, approximately 1:1 equimolar composition of cannabidiol (CBD) and cannabidiolic acid (CBDA), with THC and THCA not present — plus a second patent family combining that composition with omega fatty acids.
This work originated from research GreenWay funded at Middle Tennessee State University beginning in 2016. The priority patent application was filed in 2019 and assigned to GreenWay Herbal Products, LLC, which owns the estate.
Our focus is the continued development of cannabinoid-derived pharmaceutical candidates through disciplined scientific and regulatory pathways.
Focused on Translational Drug Development
GreenWay Herbal Products is actively pursuing the advancement of its cannabinoid intellectual property toward pharmaceutical development.
This includes continued research, formulation development, regulatory planning, and evaluation of clinical pathways appropriate for cannabinoid-based drug candidates.
Composition-of-matter and method-of-use IP
Preclinical research and pharmacological evaluation
Regulatory strategy and pathway assessment
Strategic licensing and development partnerships
GreenWay Herbal Products, LLC is not a consumer wellness brand and does not market dietary supplements as its core business.